Brucke Financial Inc. Purchases Shares of 2,289 Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• Brucke Financial Inc. has acquired a new stake in Gilead Sciences, Inc., purchasing 2,289 shares valued at approximately $244,000 in the first quarter.
• Several institutional investors, including Brighton Jones LLC and CIBC Private Wealth Group LLC, have significantly raised their stakes in Gilead Sciences during the fourth quarter.
• Analyst ratings for Gilead Sciences are largely positive, with a current consensus rating of "Moderate Buy" and a price target range between $125.00 and $135.00 from various firms.

Brucke Financial Inc. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,289 shares of the biopharmaceutical company's stock, valued at approximately $244,000.

A number of other large investors have also recently bought and sold shares of the company. XTX Topco Ltd boosted its position in Gilead Sciences by 76.8% in the 1st quarter. XTX Topco Ltd now owns 9,156 shares of the biopharmaceutical company's stock worth $1,026,000 after purchasing an additional 3,976 shares in the last quarter. Harvest Fund Management Co. Ltd boosted its position in Gilead Sciences by 20.2% in the 1st quarter. Harvest Fund Management Co. Ltd now owns 97,254 shares of the biopharmaceutical company's stock worth $10,892,000 after purchasing an additional 16,365 shares in the last quarter. Banque Cantonale Vaudoise purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $11,928,000. Meeder Advisory Services Inc. boosted its position in Gilead Sciences by 7.4% in the 1st quarter. Meeder Advisory Services Inc. now owns 29,794 shares of the biopharmaceutical company's stock worth $3,338,000 after purchasing an additional 2,049 shares in the last quarter. Finally, Hurley Capital LLC boosted its position in Gilead Sciences by 223.8% in the 1st quarter. Hurley Capital LLC now owns 518 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 358 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the completion of the transaction, the insider directly owned 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the stock in a transaction on Monday, June 30th. The stock was sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. This represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,000 shares of company stock valued at $8,984,175. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

GILD has been the topic of several recent research reports. Oppenheimer lowered their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Morgan Stanley upped their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Finally, Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. Eight analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $112.36.

Gilead Sciences Trading Down 0.0%

NASDAQ:GILD traded down $0.04 during trading hours on Friday, hitting $112.25. The company had a trading volume of 665,766 shares, compared to its average volume of 8,396,990. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. The company has a 50-day moving average of $110.40 and a 200 day moving average of $106.55. The company has a market cap of $139.63 billion, a P/E ratio of 23.61, a P/E/G ratio of 0.72 and a beta of 0.29. Gilead Sciences, Inc. has a 1 year low of $72.43 and a 1 year high of $119.96.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.